NEW YORK – In the world of biotech clichés, “multiple shots on goal,” is one that shows up frequently in executive parlance during presentations, as they boast of their companies’ diverse pipelines, mostly hoping to assure potential investors and partners that the possibilities – and the risk – are spread among a handful of programs.